EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin

Adrianna M Turner iD, Lucy Li, Ian R Monk iD, Jean Y H Lee iD, Danielle J Ingle iD, Stephanie Portelli iD, Norelle L Sherry, Nicole Isles, Torsten Seemann iD, Liam K Sharkey iD, Calum J Walsh, Gavin E Reid und 17 weitere

Nature · 28.11.2024 · 635 (8040) · 969-977

DOI: 10.1038/s41586-024-08095-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature, online erschienen am 23.10.2024. Verfasst von Adrianna M Turner und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Antibiotic Prophylaxis, Daptomycin, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health1. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action2, but for which resistance has been widely reported but is unexplained. Here we show that rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in patients with liver disease3, causes cross-resistance to daptomycin in VREfm. Amino acid changes arising within the bacterial RNA polymerase in response to rifaximin exposure cause upregulation of a previously uncharacterized operon (prdRAB) that leads to cell membrane remodelling and cross-resistance to daptomycin through reduced binding of the antibiotic. VREfm with these mutations are spread globally, making this a major mechanism of resistance. Rifaximin has been considered 'low risk' for the development of antibiotic resistance. Our study shows that this assumption is flawed and that widespread rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin, a major last-resort intervention for multidrug-resistant pathogens. These findings demonstrate how unanticipated antibiotic cross-resistance can undermine global strategies designed to preserve the clinical use of critical antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAntibiotic ProphylaxisDaptomycinDrug Resistance, Multiple, BacterialEnterococcus faeciumHepatic EncephalopathyRifaximinAnimalsFemaleHumansMiceDNA-Directed RNA PolymerasesGram-Positive Bacterial InfectionsLiver CirrhosisMice, Inbred C57BLMutationOperonVancomycin

Substanzen

Anti-Bacterial AgentsDaptomycinDNA-Directed RNA PolymerasesRifaximinVancomycin

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Department of Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
  • Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • School of Chemistry and Molecular Biosciences, The University of Queensland, Saint Lucia Campus, Saint Lucia, Queensland, Australia.
  • Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Department of Infectious Diseases & Immunology, Austin Health, Melbourne, Victoria, Australia.

ORCID-Profile: Adrianna M Turner, Ian R Monk, Jean Y H Lee, Danielle J Ingle, Stephanie Portelli, Torsten Seemann, Liam K Sharkey, Bart A Eijkelkamp, David B Ascher, Sebastian Duchene, Nichollas E Scott, Timothy P Stinear, Claire L Gorrie, Benjamin P Howden, Glen P Carter

Zitieren

APA

Turner, A. M., Li, L., Monk, I. R., Lee, J. Y. H., Ingle, D. J., Portelli, S., Sherry, N. L., Isles, N., Seemann, T., Sharkey, L. K., Walsh, C. J., Reid, G. E., Nie, S., Eijkelkamp, B. A., Holmes, N. E., Collis, B., Vogrin, S., Hiergeist, A., Weber, D., …, & Carter, G. P. (2024). Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature, 635(8040), 969-977. https://doi.org/10.1038/s41586-024-08095-4

Vancouver

Turner AM, Li L, Monk IR, Lee JYH, Ingle DJ, Portelli S, et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature. 2024;635(8040):969-977. doi:10.1038/s41586-024-08095-4

BibTeX
@article{Turner2024,
  author = {Turner, Adrianna M and Li, Lucy and Monk, Ian R and Lee, Jean Y H and Ingle, Danielle J and Portelli, Stephanie and Sherry, Norelle L and Isles, Nicole and Seemann, Torsten and Sharkey, Liam K and Walsh, Calum J and Reid, Gavin E and Nie, Shuai and Eijkelkamp, Bart A and Holmes, Natasha E and Collis, Brennan and Vogrin, Sara and Hiergeist, Andreas and Weber, Daniela and Gessner, Andre and Holler, Ernst and Ascher, David B and Duchene, Sebastian and Scott, Nichollas E and Stinear, Timothy P and Kwong, Jason C and Gorrie, Claire L and Howden, Benjamin P and Carter, Glen P},
  title = {Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin},
  journal = {Nature},
  year = {2024},
  volume = {635},
  number = {8040},
  pages = {969--977},
  doi = {10.1038/s41586-024-08095-4}
}
Kostenlos starten →